Liraglutide protected against indomethacin-induced gastric damage in a preclinical model, adding gastroprotection to GLP-1 drug benefits through anti-inflammatory mechanisms.
Key findingLiraglutide protected against indomethacin-induced gastric damage in a preclinical model, adding gas
What the researchers found
Liraglutide protected against indomethacin-induced gastric damage in a preclinical model, adding gastroprotection to GLP-1 drug benefits through anti-inflammatory mechanisms.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
63 male Wistar rats in 7 groups. STZ for diabetes induction. Indomethacin for ulcer induction. Liraglutide at 0.2 mg/kg and 0.4 mg/kg. Compared to omeprazole.
How the study worked
In publication.
Who was studied
Male Wistar rats with streptozotocin-induced diabetes
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
The effect of liraglutide, a GLP-1 analog, on indomethacin-induced gastric ulcers in diabetic rats.
Acta cirurgica brasileira, 40, e407325
Citation
Arslan, Huseyin Emre; Teksen, Yasemin; Ozatik, Orhan; Algin, Mustafa Cem. (2025). The effect of liraglutide, a GLP-1 analog, on indomethacin-induced gastric ulcers in diabetic rats.. Acta cirurgica brasileira, 40, e407325. https://doi.org/10.1590/acb407325